PubRank

Young Plasma Transfusions for Progressive Supranuclear Palsy

Clinical Trial ID NCT02460731

PubWeight™ 0.77‹?›

🔗 Visit the ClinicalTrials.gov page for NCT02460731

Top papers

Rank Title Journal Year PubWeight™‹?›
1 "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975 301.74
2 Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 1983 41.26
3 The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011 24.26
4 The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol 1998 9.33
5 PROGRESSIVE SUPRANUCLEAR PALSY. A HETEROGENEOUS DEGENERATION INVOLVING THE BRAIN STEM, BASAL GANGLIA AND CEREBELLUM WITH VERTICAL GAZE AND PSEUDOBULBAR PALSY, NUCHAL DYSTONIA AND DEMENTIA. Arch Neurol 1964 9.20
6 Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996 8.82
7 The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature 2011 6.71
8 Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet 1999 3.94
9 Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997 3.77
10 Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice. Nat Med 2014 3.75
11 Vascular and neurogenic rejuvenation of the aging mouse brain by young systemic factors. Science 2014 3.37
12 A clinical rating scale for progressive supranuclear palsy. Brain 2007 2.71
13 Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol 2014 1.89
14 Development of methodology for conducting clinical trials in frontotemporal lobar degeneration. Brain 2008 1.82
15 Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. Brain 2008 1.72
16 Prevalence and natural history of progressive supranuclear palsy. Neurology 1988 1.54
17 Sleep and circadian rhythm regulation in early Parkinson disease. JAMA Neurol 2014 1.50
18 Comparison of analytical platforms for cerebrospinal fluid measures of β-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology. Arch Neurol 2011 1.50
19 Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). Neurology 1996 1.32
20 Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination. J Neurol Neurosurg Psychiatry 1998 1.25
21 Adverse effects of plasma transfusion. Transfusion 2012 1.23
22 Measuring quality of life in PSP: the PSP-QoL. Neurology 2006 0.96
23 Equivalence of the Color Trails Test and Trail Making Test in nonnative English-speakers. Arch Clin Neuropsychol 2000 0.94
24 Intrinsic connectivity network disruption in progressive supranuclear palsy. Ann Neurol 2013 0.91
25 ADNP: in search for molecular mechanisms and innovative therapeutic strategies for frontotemporal degeneration. Front Aging Neurosci 2015 0.77
Next 100